Mesenchymal precursor cells regulatory update

Japan approved an NDA from JCR Pharmaceuticals for Temcell to treat graft-versus-host disease (GvHD) in children and adults. JCR and partner Mesoblast said Temcell is the first allogeneic regenerative medicine product to gain approval in Japan. The product comprises allogeneic adult mesenchymal precursor cells (MPCs) used to expand cord blood by up to fortyfold. ...